Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor Seliciclib

Chronobiology International

Volumn 26, Issue 6, 2009, Pages 1169-1188

  Iurisci, Ida ^a,b,c   Filipski, Elisabeth ^a,b   Sallam, Hatem ^d   Harper, Francis ^e   Guettier, Catherine ^f   Maire, Irène ^g   Hassan, Moustapha ^d   Iacobelli, Stefano ^c   Lévi, Francis ^a,b,f  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF CHIETI   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e CNRS   (France)

^f HÔPITAL PAUL BROUSSE   (France)

^g Centre de Biologie et de Pathologie Est   (France)

Author keywords

Chonopharmacology; Circadian clock; Drug metabolism; Liver toxicity; Seliciclib

Indexed keywords

GLYCOGEN; LIVER ENZYME; MESSENGER RNA; PER2 PROTEIN; ROSCOVITINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHEMICAL ANALYSIS; CIRCADIAN RHYTHM; CONTROLLED STUDY; DARKNESS; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG EXPOSURE; ELECTRON MICROSCOPY; GENE EXPRESSION; LIVER CELL; MALE; MOLECULAR CLOCK; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TIME; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL CLOCKS; CELL CYCLE; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; GASTROINTESTINAL DISEASES; GENE EXPRESSION REGULATION; LIVER; MALE; MICE; PURINES;

MUS;

EID: 70349158728     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.1080/07420520903209942     Document Type: Article

References (45)

1. Akashi M, Tsuchiya Y, Yoshino T, Nishida E. (2002). Control of intracellular dynamics of mammalian period proteins by casein kinase I epsilon (CKIepsilon) and CKIdelta in cultured cells. Mol. Cell. Biol. 22:1693-1703.
2. Bachmeier CJ, Miller DW. (2005). A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier. Pharm. Res. 22:113-121.
3. Bruguerolle B. (1998). Chronopharmacokinetics. Current status. Clin. Pharmacokinet. 35:83-94.
4. Dardente H, Cermakian N. (2007). Molecular circadian rhythms in central and peripheral clocks in mammals. Chronobiol. Int. 24:195-213.
5. De Prins J, Hecquet B. (1992). In Touitou Y, Haus E (eds). Biological rhythms in clinical and laboratory medicine. Berlin: Springer Verlag, pp. 90-112.
6. Eide EJ, Woolf MF, Kang H, Woolf P, Hurst W, Camacho F, Vielhaber EL, Giovanni A, Virshup DM. (2005). Control of mammalian circadian rhythm by CKIepsilon-regulated proteasome-mediated PER2 degradation. Mol. Cell. Biol. 25:2795-2807.
7. Etienne-Grimaldi MC, Cardot JM, François E, Renée N, Douillard JY, Gamelin E, Bennouna J, Château Y, Milano G. (2007). Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients. Clin. Pharmacol. Ther. 83:413-415.
8. Filipski E, King VM, Li XM, Granda TG, Mormont MC, Liu XH, Claustrat B, Hastings MH, Lévi F. (2002). Host circadian clock as a control point in tumor progression. J. Nat. Cancer Inst. 94:690-697.
9. Filipski E, Delaunay F, King VM, Wu MW, Claustrat B, Grechez-Cassiau A, Guettier C, Hastings MH, Lévi F. (2004). Effects of chronic jet lag on malignant growth in mice. Cancer Res. 64:7879-7885.
10. Filipski E, Innominato PF, Wu M, Li XM, Iacobelli S, Xian LJ, Lévi F. (2005). Effects of light and food schedules on liver and tumor molecular clock. J. Nat. Cancer Inst. 97:507-517.
11. Fu L, Lee CC. (2003). The circadian clock: Pacemaker and tumour suppressor. Nat. Rev. Cancer. 3:350-361.
12. Fu L, Pelicano H, Liu J, Huang P, Lee CC. (2002). The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41-50.
13. Gachon F, Olela FF, Schaad O, Descombes P, Schibler U. (2006). The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 4:25-36.
14. Gallego M, Virshup DM. (2007). Post-translational modifications regulate the ticking of the circadian clock. Nat. Rev. Mol. Cell Biol. 8:139-148.
15. Haus E. (2007). Circadian disruption in shiftwork is probably carcinogenic to humans. Chronobiol. Int. 24:1255-1256.
16. Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchetti S, Coudert B, Iaco-belli S, Genet D, Tampellini M, Chollet P, Lentz MA, Mormont MC, Lévi F, Bjarnason GA, for the ARTBC Chronotherapy Group. (2009). Circadian rhythm in rest and activity: A biological correlate of health-related quality of life and a predictor of survival in patients with metastatic col-orectal cancer. Cancer Res. 69:4700-4707.
17. Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, Meijer L, Lévi F. (2006). Improved tumor control through circadian clock induction by seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 66:10720-10728.
18. Knockaert M, Greengard P, Meijer L. (2002). Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23:417-425.
19. Labrecque G, Sirois-Labrecque M. (2003). Chronopharmacologie. Rythmes biologiques et administration des médicaments. Canada: Les Presses de l'Univ. de Montréal, Montréal, 420 pp.
20. Lemmer B. (2006). The importance of circadian rhythms on drug response in hypertension and coronary heart disease-from mice and man. Pharmacol. Ther. 111:629-651.
21. Lévi F, Schibler U. (2007). Circadian rhythms: Mechanisms and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 47:593-628.
22. Lévi F, Filipski E, Iurisci I, Li XM, Innominato P (ed.). (2007). Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harbor Symposia on Quantitative Biology. Vol.LXXII. Cold Spring Harbour Laboratory Press, Woodbury, NY, pp. 1-11.
23. Li XM, Lévi F. (2007). Circadian physiology is a toxicity target of the anticancer drug gemcitabine in mice. J. Biol. Rhythms 22:159-166.
24. Luft JH. (1961). Improvements in epoxy resin embedding methods. J. Biophys. Biochem. Cytol. 9:409-414.
25. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. (2003). Control mechanism of the circadian clock for timing of cell division in vivo. Science 302:255-259.
26. McClue SJ, Stuart I. (2008). Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab. Disp. 36:561-570.
27. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP. (1997). Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-depedent kinases cdc2, cdk2, and cdk5. Eur. J. Biochem. 243:527-536.
28. Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, Lellouch J, Misset JL, Touitou Y, Lévi F. (2000). Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin. Cancer Res. 6:3038-3045.
29. Ohdo S, Suyama H, Higuchi S, Aramaki H. (2001). Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat. Med. 7:356-360.
30. Oklejewicz M, Destici E, Tamanini F, Hut RA, Janssens R, van der Horst GT. (2008). Phase resetting of the mammalian circadian clock by DNA damage. Curr. Biol. 18:286-291.
31. Phelps M, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Booker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT. (2009). Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 113:2637-2645.
32. Portaluppi F, Touitou Y, Smolensky M. (2008). Ethical and methodological standards for laboratory and medical biological rhythm research. Chronobiol. Int. 25:999-1016.
33. Qu X, Metz RP, Porter WW, Cassone VM, Earnest DJ. (2009). Disruption of period gene expression alters the inductive effects of dioxin on the AhR signaling pathway in the mouse liver. Toxicol. Appl. Pharmacol. 234:370-377.
34. Radzialowski FM, Bousquet WF. (1967). Daily rhythmic variation in hepatic drug metabolism in the rat and mouse. J. Pharmacol. Exp. Ther. 163:229-238.
35. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. (2000). Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl. Cancer Inst. 92:994-1000.
36. Sidbury JB, Jr, Cornblath M, Fisher J, House E. (1961). Glycogen in erythrocytes of patients with glycogen storage disease. Pediatrics 27:103-111.
37. Siegel-Lakhai, W, S, Rodenstein, D, O, Beijnen, J, H, Gianella-Borradori, A, Schellens, J, H, & Talbot, D, C (2005). Phase IIa study of seliciclib (CYC202 or R-roscovitine) in combination with gemcita-bine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC). Abstract 2060. American Society of Clinical Oncology Annual Meeting, Orlando, Florida, 13-17 May.
38. Smith RD, Turek FW, Takahashi JS. (1992). Two families of phase-response curves characterize the resetting of the hamster circadian clock. Am. J. Physiol. 262(6 Pt 2):R1149-R1153.
39. Smolensky M, Peppas N. (2007). Chronobiology, drug delivery and chronotherapeutics. Adv. Drug Deliv. Rev. 59:828-851.
40. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, Ben Brahim-Tallaa L, Cogliano V, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group. (2007). Carcinogenicity of shift work, painting and firefighting. Lancet Oncol. 8:1065-1066.
41. Summer TL, Ferraro JS, McCormack CE. (1984). Phase-response and Aschoff illuminance curves for locomotor activity rhythm of the rat. Am. J. Physiol. 246:R299-R304.
42. Terazono H, Hamdan A, Matsunaga N, Hayasake N, Kaji H, Egawa T, Makino K, Shigeyoshi Y, Koyo-nagi S, Ohdo S. (2008). Modulatory effects of 5-fluorouracil on the rhythmic expression of circadian clock genes: A possible mechanism of chemotherapy-induced circadian rhythm disturbances. Biochem. Pharmacol. 75:1616-1622.
43. Vita M, Meurling L, Pettersson T, Cruz-Sidén M, Sidén A, Hassan M. (2004). Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: Pharmacoki-netics of roscovitine in rat. J. Pharm. Biomed. Anal. 34:425-431.
44. Vita M, Abdel-Rehim M, Olofsson S, Hassan Z, Meurling L, Sidén A, Sidén M, Pettersson T, Hassan M. (2005). Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur. J. Pharm. Sci. 25:91-103.
45. Zhang YK, Yeager RL, Klaassen CD. (2008). Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. Drug Metab. Dispos. 37:106-115.